X.T.L. Biopharmaceuticals Ltd
Research X.T.L. Biopharmaceuticals Ltd (XTLB) on Bullrun: market cap USD 6.15M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXTLB
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.15M
- Financial periodQ4 2025
Valuation Snapshot
latest market cap is USD 6.15M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | USD 451.00K | -USD 1.03M | n/a | n/a | n/a | USD 371.00K | USD 138.00K | USD 5.44M |
| FY2023 | USD 0 | -USD 1.78M | n/a | n/a | n/a | USD 1.40M | n/a | USD 2.22M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.15M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 5.11M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 17.89M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 5.50M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 6.59M | 23.0 | n/a | n/a |
| 2021 | 2021-12-31 | USD 15.09M | 138.5 | n/a | n/a |
About X.T.L. Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is X.T.L. Biopharmaceuticals Ltd's market cap?
X.T.L. Biopharmaceuticals Ltd's market capitalization is USD 6.15M.
What does X.T.L. Biopharmaceuticals Ltd do?
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd.